Case Study

Closed Manufacturing System For Autologous Cell Therapy Production

Source: Invetech
iStock-1221576332-cell

A common challenge in the emerging cell and gene therapy industry is translating manual production methods to clinical and commercial-scale manufacturing. Recently, a clinical-stage biopharmaceutical company was looking to commercialize an autologous Dendritic cell therapy, an immunotherapeutic approach for treating and preventing cancers and autoimmune diseases. The company approached Invetech during Phase II clinical trials to commence development of scaled-out GMP manufacturing solutions.

In briefing Invetech, two key challenges were identified:

  • The therapy needed to be produced consistently and repeatedly at a lower cost
  • The manual benchtop process was required to be closed in a way that was suited to automation and scale-out yet supported effective biochemistry.

Invetech was engaged to develop a complete manufacturing system that would become the backbone of the client’s entire purpose-built manufacturing facility plans.

VIEW THE CASE STUDY!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene